Literature DB >> 16316590

Newer agents for the treatment of painful diabetic peripheral neuropathy.

Roy Freeman1.   

Abstract

Neuropathic pain is responsible for a significant amount of the morbidity associated with generalized and focal peripheral neuropathies in diabetes. It is a consequence of alterations in neuronal function, chemistry, and structure that occur secondary to nerve injury. A variety of agents from diverse pharmacologic classes, the so-called adjuvant analgesics, have been used to treat neuropathic pain. These include antidepressants, first- and second-generation anticonvulsants, antiarrhythmic agents, topical agents, N-methyl-d-aspartate receptor antagonists, and the opioid analgesics. The availability of several newer agents, used alone or in combination, has resulted in the successful alleviation of neuropathic pain in many patients. Recent advances in the understanding of pain mechanisms at multiple central nervous system levels should pave the way toward more effective treatment modalities with less prominent side effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16316590     DOI: 10.1007/s11892-005-0047-7

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  96 in total

1.  Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy.

Authors:  E Lang; H A Hord; D Denson
Journal:  Pain       Date:  1996-11       Impact factor: 6.961

2.  The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels.

Authors:  S H Sindrup; C Madsen; K Brøsen; T S Jensen
Journal:  Clin Pharmacol Ther       Date:  1999-12       Impact factor: 6.875

3.  Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.

Authors:  S H Sindrup; F W Bach; C Madsen; L F Gram; T S Jensen
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

4.  Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.

Authors:  M B Max; S A Lynch; J Muir; S E Shoaf; B Smoller; R Dubner
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

5.  Activation of protein kinase C augments peptide release from rat sensory neurons.

Authors:  L A Barber; M R Vasko
Journal:  J Neurochem       Date:  1996-07       Impact factor: 5.372

6.  Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.

Authors:  Smriti Iyengar; Amy A Webster; Susan K Hemrick-Luecke; Jimmy Yu Xu; Rosa Maria A Simmons
Journal:  J Pharmacol Exp Ther       Date:  2004-07-13       Impact factor: 4.030

7.  A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team.

Authors:  K Kieburtz; D Simpson; C Yiannoutsos; M B Max; C D Hall; R J Ellis; C M Marra; R McKendall; E Singer; G J Dal Pan; D B Clifford; T Tucker; B Cohen
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

8.  Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.

Authors:  R B Raffa; E Friderichs; W Reimann; R P Shank; E E Codd; J L Vaught
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

9.  Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices.

Authors:  David J Dooley; Cindy M Donovan; Wolfgang P Meder; Steven Z Whetzel
Journal:  Synapse       Date:  2002-09-01       Impact factor: 2.562

10.  Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.

Authors:  S Neil Vaishnavi; Charles B Nemeroff; Susan J Plott; Srinivas G Rao; Jay Kranzler; Michael J Owens
Journal:  Biol Psychiatry       Date:  2004-02-01       Impact factor: 13.382

View more
  1 in total

1.  Phenyl(thio)phosphon(amid)ate Benzenesulfonamides as Potent and Selective Inhibitors of Human Carbonic Anhydrases II and VII Counteract Allodynia in a Mouse Model of Oxaliplatin-Induced Neuropathy.

Authors:  Alessio Nocentini; Vincenzo Alterio; Silvia Bua; Laura Micheli; Davide Esposito; Martina Buonanno; Gianluca Bartolucci; Sameh M Osman; Zeid A ALOthman; Roberto Cirilli; Marco Pierini; Simona Maria Monti; Lorenzo Di Cesare Mannelli; Paola Gratteri; Carla Ghelardini; Giuseppina De Simone; Claudiu T Supuran
Journal:  J Med Chem       Date:  2020-05-14       Impact factor: 7.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.